<DOC>
	<DOCNO>NCT01950221</DOCNO>
	<brief_summary>This project design study whether pomegranate extract benefit cognitive ability middle-aged old non-demented volunteer . Subjects randomly assign one two treatment group : either placebo pomegranate extract supplement . Both placebo pomegranate extract package 1000 milligram capsule maintain blindness . Subjects take one 1000 milligram capsule daily twelve month . The investigator expect people receive pomegranate extract supplement show well cognitive performance compare receive placebo one , six , twelve month . The investigator believe cognitive decline treatment response vary accord genetic risk Alzheimer 's . The investigator study 212 non-demented subject age 50-75 year . Initially , subject undergo clinical assessment , MRI blood draw determine genetic risk rule neurodegenerative disorder link memory complaint . Subsequently , subject undergo first memory ( neuropsychological ) assessment . Following first assessment , subject begin take supplement ( either pomegranate extract placebo ) . Subjects undergo brief memory test one-month mark . At six month , subject second , full neuropsychological assessment . The final assessment take place end study , 12-month mark . Additional blood drawn baseline 12 month frozen assess inflammatory marker outcomes positive . Subjects also ask come University California , Los Angeles ( UCLA ) 3 9 month supplement refill . In total , subject expect come UCLA 7 visit course 12-13 month .</brief_summary>
	<brief_title>Pomegranate Extract Memory</brief_title>
	<detailed_description />
	<criteria>Agreement participate 12month doubleblind , placebocontrolled clinical trial pomegranate extract . Nondemented subject either normal cognition Mild Cognitive Impairment include . Age 50 75 year . No significant cerebrovascular disease : modify Ischemic Score &lt; 4 Adequate visual auditory acuity allow neuropsychological testing . Screening laboratory test EKG without significant abnormality might interfere study . If screening laboratory test EKG show abnormality , subject must obtain write clearance primary care physician continue study . Diagnosis probable Alzheimer 's disease ( AD ) dementia ( e.g. , vascular , Lewy body , frontotemporal ) ( McKhann et al , 1984 ) . Evidence neurological physical illness produce cognitive deterioration . Volunteers history stroke , Transient Ischemic Attack ( TIA ) , carotid bruits , lacunes MRI scan exclude . Determination dementia base clinical evaluation include assessment functional ability , cognitive screening . Contraindication MRI include claustrophobia , metal body , surgery within 60 day , certain implant previous abnormal MRI result . Evidence Parkinson 's disease determine motor examination ( item 1831 ) Unified Parkinson 's Disease Rating Scale ( Fahn et al , 1987 ) . History myocardial infarction within previous year , unstable cardiac disease . Uncontrolled hypertension ( systolic BP &gt; 170 diastolic BP &gt; 100 ) . History significant liver disease , clinicallysignificant pulmonary disease , diabetes . Current diagnosis major psychiatric disorder Current diagnosis history alcoholism substance addiction . Regular use medication may affect cognitive function include : centrally active betablockers , narcotic , Clonidine , antiParkinsonian medication , antipsychotic , systemic corticosteroid , medication significant cholinergic anticholinergic effect , anticonvulsant , Warfarin . Occasional use anxiety sleep medication know cause cognitive dulling allow , discourage : chloral hydrate , nonbenzodiazepine hypnotic : Ambien ( Zolpidem ) Lunesta ; benzodiazepine Ativan ( Lorazepam ) , Xanax ( Alprazolam ) , Klonopin ( Clonazepam ) , Restoril ( Temazepam ) . Use following medication : Amitriptyline , Amiodarone , Desipramine , Fenofibrate , Flecainide , Fluconazole , Fluoxetine , Fluvastatin , Fluvoxamine , Isoniazid , Lovastatin , Ondansetron , Phenylbutazone , Probenecid , Sertraline , Sulfamethoxazole , Sulfaphenazole , Teniposide , Voriconazole , Warfarin , Zafirlukast Use cognitive enhancing supplement ( e.g . Ginkgo biloba ) . Use supplement contain pomegranate pomegranate juice . Use investigational drug within previous month longer , depend drug halflife . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Double-blind Trial</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Pomegranate</keyword>
	<keyword>Memory</keyword>
	<keyword>Memory Impairment</keyword>
	<keyword>Cognition</keyword>
	<keyword>Ages 50-75</keyword>
</DOC>